By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
A form of shape memory alloy used in medical equipment is nitinol. The name “Nickel Titanium Naval Ordnance Laboratories” refers to the company that was responsible for discovering the alloy’s special characteristics.
As a result of being bent, twisted, or otherwise distorted, the nickel and titanium alloy known as nitinol can regain its previous shape.
Nitinol is ideally suited for application in medical devices because of this characteristic. It may be utilised to construct flexible components that, when subjected to heat or other stimuli, will take on their original shape.
Self-expanding grafts, bins, filters, connection supporting frameworks, and other items are only a few examples of the many uses for nitinol.
The super-versatility and thermal shape memory of nitinol compounds are what make them most famous. Nitinol, a compound of titanium and nickel, is used to make medical equipment. Nitinol-based guidewires and stents have improved operative outcomes.
The Nitinol Medical Devices accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
The EasyFuse Dynamic Compression System, made of the nickel-titanium alloy metal Nitinol, was introduced by Stryker Corporation. Reduced surgical complexity and operating room waste are the material’s goals, as well as its strength and form recovery.
The maker of medical equipment and parts constructed of the shape-memory alloy nitinol, Endosmart Gesellschaft für Medizintechnik GmbH (Endosmart), with headquarters in Germany, was bought by Alleima.
The product line comprises surgical instruments, breast cancer tumour markers, and baskets and snares for removing kidney stones.
To offer a better digital and self-serve client experience, Cook Medical recently announced the establishment of a new customer portal.
The DIRECTSENSE Technology, a device for observing the impact of radiofrequency (RF) energy delivery during cardiac ablation procedures, is officially launched in the United States, according to Boston Scientific.
Celularity Inc., a clinical-stage biotechnology business, and Arthrex Inc., a world pioneer in minimally invasive orthopaedic technology, announced they have formed an exclusive agreement to distribute and market Celularity’s biomaterial products for orthopaedic surgery and sports medicine.
Both firms are developing novel cell treatments and biomaterial products derived from the postpartum human placenta to treat cancer, infectious, and degenerative illnesses.
